FLONASE SENSIMIST ALLERGY RELIEF
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FLONASE SENSIMIST ALLERGY RELIEF (FLONASE SENSIMIST ALLERGY RELIEF).
Fluticasone propionate is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines, suppression of inflammatory cell migration, and reduction of mucosal edema.
| Metabolism | Hepatic via CYP3A4 to inactive metabolites |
| Excretion | Fluticasone propionate is eliminated primarily via hepatic metabolism and subsequent renal excretion. Following oral administration, approximately 87-90% of the dose is excreted in feces as metabolites, with less than 5% excreted unchanged in urine. After intranasal administration, the swallowed portion undergoes first-pass metabolism, and systemic absorption is minimal; the eliminated fraction follows the same pattern. |
| Half-life | The terminal elimination half-life of fluticasone propionate after intravenous administration is approximately 7.8 hours. After intranasal administration, due to slow absorption from the nasal mucosa and extensive first-pass metabolism, the apparent half-life is prolonged, ranging from 10 to 15 hours, reflecting the flip-flop pharmacokinetics. |
| Protein binding | Fluticasone propionate is approximately 91% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | The volume of distribution at steady state (Vdss) is approximately 4.2 L/kg, indicating extensive tissue distribution. This large Vd reflects high lipophilicity and tissue binding. |
| Bioavailability | Intranasal bioavailability is less than 2% due to low systemic absorption and extensive first-pass metabolism of the swallowed portion. Oral bioavailability is negligible (<1%) due to first-pass metabolism. |
| Onset of Action | Onset of action for relief of seasonal allergic rhinitis symptoms occurs within 12 hours after the first intranasal dose, with clinically significant improvement seen in some patients by 12 hours and maximum benefit observed after several days of regular use. |
| Duration of Action | Duration of action is 24 hours, allowing once-daily dosing (200 mcg per day). Symptom control is maintained with regular daily use; however, individual response may vary. |
| Molecular Weight | 500.57 |
110 mcg (2 sprays) intranasally once daily; after 1 week, may reduce to 55 mcg (1 spray) per nostril once daily for maintenance.
| Dosage form | SPRAY, METERED |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Children 2-11 years: 55 mcg (1 spray) per nostril intranasally once daily. Children 12 years and older: same as adult dosing. |
| Geriatric use | No dose adjustment required; use with caution in elderly due to potential increased sensitivity. |
| 1st trimester | Insufficient data in humans; animal studies show no teratogenic effects. Use only if clearly needed. |
| 2nd trimester | No known risk in humans; nasal corticosteroids are preferred for rhinitis treatment. |
| 3rd trimester | Use with caution in late pregnancy due to potential risk of fetal adrenal suppression with high doses. |
Clinical note
Comprehensive clinical and safety monograph for FLONASE SENSIMIST ALLERGY RELIEF (FLONASE SENSIMIST ALLERGY RELIEF).
| Placental transfer | Minimal due to low systemic bioavailability after intranasal use; not expected to cross placenta in significant amounts. |
| Breastfeeding | Fluticasone propionate (active ingredient) is excreted in breast milk in negligible amounts following intranasal administration; unlikely to affect nursing infant. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to fluticasone propionate or any excipientsUntreated nasal mucosal infection (e.g., herpes simplex)
| Precautions | May cause epistaxis, nasal ulceration, or nasal septal perforation, Monitor for signs of hypercorticism with prolonged use, Risk of immunosuppression and increased susceptibility to infections, Use caution in patients with tuberculosis or untreated fungal/bacterial/viral infections, May delay wound healing after nasal surgery or trauma |
| Food/Dietary | No significant food interactions. Grapefruit juice does not affect intranasal fluticasone. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating |
| L1 (Safe) |
| Teratogenic Risk | FDA Pregnancy Category C. Inhaled corticosteroid fluticasone propionate has not demonstrated significant teratogenicity in animal studies at doses exceeding clinical exposure. First trimester: No increased risk of major congenital malformations from population-based studies. Second and third trimesters: Risk of fetal growth restriction with prolonged high-dose use. Monitor for adrenal suppression in neonates if maternal treatment continues to term. |
| Fetal Monitoring | Monitor fetal growth via ultrasound if long-term treatment. Maternal assessment for adrenal suppression (rare). Neonatal observation for signs of adrenal insufficiency (hypoglycemia, lethargy) if maternal use in late gestation. |
| Fertility Effects | No evidence of impaired fertility from animal studies. No human data on fertility effects; theoretical risk of hypothalamic-pituitary-adrenal axis suppression with high systemic absorption, but intranasal route minimizes systemic exposure. |
| Fluticasone propionate intranasal spray is a first-line therapy for allergic rhinitis. Onset of action is 12 hours; maximal benefit may take several days to 2 weeks. Proper administration technique (tilting head forward, spraying away from nasal septum) improves efficacy and reduces epistaxis. May cause nasal dryness or epistaxis; lubricate nasal mucosa if needed. No significant systemic absorption at recommended doses; safe for long-term use. |
| Patient Advice | Use regularly for best results; it is not for immediate relief. · Prime the spray with 4 test sprays before first use or if not used for 7 days. · Blow nose gently before each use. · Tilt head forward slightly, insert nozzle into nostril, and spray away from the septum. · Do not use more than the recommended dose; avoid contact with eyes. · Rinse spray tip with warm water and dry after each use. · May cause nasal irritation or nosebleeds; discontinue if severe. |